JP2022502508A5 - - Google Patents
Info
- Publication number
- JP2022502508A5 JP2022502508A5 JP2021542087A JP2021542087A JP2022502508A5 JP 2022502508 A5 JP2022502508 A5 JP 2022502508A5 JP 2021542087 A JP2021542087 A JP 2021542087A JP 2021542087 A JP2021542087 A JP 2021542087A JP 2022502508 A5 JP2022502508 A5 JP 2022502508A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- ptcl
- cell lymphoma
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739631P | 2018-10-01 | 2018-10-01 | |
| US62/739,631 | 2018-10-01 | ||
| PCT/US2019/054107 WO2020072519A1 (en) | 2018-10-01 | 2019-10-01 | Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502508A JP2022502508A (ja) | 2022-01-11 |
| JP2022502508A5 true JP2022502508A5 (cg-RX-API-DMAC7.html) | 2022-10-11 |
Family
ID=68296746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542087A Pending JP2022502508A (ja) | 2018-10-01 | 2019-10-01 | 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200102399A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3860658A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022502508A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210069679A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113613678A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019355875A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114922A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL281920A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021003734A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103342QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020072519A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| KR20230023650A (ko) * | 2020-05-13 | 2023-02-17 | 씨젠 인크. | 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법 |
| CN116964098A (zh) | 2021-03-01 | 2023-10-27 | 南特生物公司 | 抗cd30单克隆抗体和嵌合抗原受体 |
| WO2024145637A2 (en) * | 2022-12-30 | 2024-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Immunotoxin-based targeted therapy for cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| MA46759A (fr) * | 2016-11-14 | 2019-09-18 | Millennium Pharm Inc | Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte |
| KR20200080274A (ko) * | 2017-11-01 | 2020-07-06 | 시애틀 지네틱스, 인크. | 항-cd30 항체 약물 컨쥬게이트 요법의 부작용을 감소시키는 방법 |
-
2019
- 2019-10-01 MX MX2021003734A patent/MX2021003734A/es unknown
- 2019-10-01 AU AU2019355875A patent/AU2019355875A1/en not_active Abandoned
- 2019-10-01 WO PCT/US2019/054107 patent/WO2020072519A1/en not_active Ceased
- 2019-10-01 CA CA3114922A patent/CA3114922A1/en active Pending
- 2019-10-01 SG SG11202103342QA patent/SG11202103342QA/en unknown
- 2019-10-01 KR KR1020217012841A patent/KR20210069679A/ko not_active Ceased
- 2019-10-01 EP EP19791017.7A patent/EP3860658A1/en active Pending
- 2019-10-01 CN CN201980071250.5A patent/CN113613678A/zh active Pending
- 2019-10-01 JP JP2021542087A patent/JP2022502508A/ja active Pending
- 2019-10-01 US US16/589,914 patent/US20200102399A1/en active Pending
-
2021
- 2021-03-31 IL IL281920A patent/IL281920A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020222295B2 (en) | Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor | |
| Gazzah et al. | Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study | |
| CN101686971B (zh) | 用于治疗多发性骨髓瘤的药物产品及其用途 | |
| JP6177133B2 (ja) | Cd38を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| CN103118706B (zh) | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl | |
| JP2023508496A5 (cg-RX-API-DMAC7.html) | ||
| Minich | Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma | |
| JP2019503387A5 (cg-RX-API-DMAC7.html) | ||
| Cheng et al. | Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors | |
| JP2021518394A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500822A5 (cg-RX-API-DMAC7.html) | ||
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| JP2021501776A5 (cg-RX-API-DMAC7.html) | ||
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| JP2021523233A5 (cg-RX-API-DMAC7.html) | ||
| JP2021523158A5 (cg-RX-API-DMAC7.html) | ||
| CA2156579A1 (en) | Method of treating vascular leak syndrome | |
| JP2023500697A5 (cg-RX-API-DMAC7.html) | ||
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| JP2022164894A (ja) | 非成人のヒトに対する抗cd30抗体-薬物コンジュゲートの投与 | |
| JP2021501800A5 (cg-RX-API-DMAC7.html) | ||
| JPH01502909A (ja) | 免疫毒素による人間の治療における免疫抑制 | |
| TWI832866B (zh) | 醫藥組合 | |
| Goldsmith et al. | Bispecific antibodies for the treatment of multiple myeloma |